Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Organic Chemicals
Hydrocarbons
Clear Filters

Search Clinical Trials

39 Results
Completed
Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma
Induction Phase Overview The induction phase is approximately 15 weeks long. Chemotherapy is generally given every 3 weeks, each 3 week block is called a "cycle". During these 15 weeks …
Baylor Role: Lead Sponsor
Completed
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
The major objective of this two-stage phase II study is to determine whether tamoxifen is deserving of further study in metastatic bladder cancer. Tamoxifen is expected to function as a …
Completed
Research Study for Major Depressive Disorder: Investigation of Glutamate Medications
This research proposal will investigate a glutamate-modulating agent, riluzole, in treatment-resistant patients who exhibit an acute, sustained response to a single dose of intravenous (IV) racemic ketamine. Fifty ketamine-responders will …
Baylor Role: Lead Sponsor
Completed
Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
Patients were enrolled over 11 months from the Parkinson Disease Center and Movement Disorder Clinic at Baylor College of Medicine. PD was diagnosed using standard criteria. Specific inclusion criteria were …
Baylor Role: Lead Sponsor
Completed
Effect of Curcumin on Lung Inflammation
Chronic obstructive pulmonary disease (COPD) and lung cancer are leading causes of death and health care use. Diffuse airways inflammation is seen in COPD and is thought to be the …
Baylor Role: Lead Sponsor
Completed
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
Large clinical trials have confirmed the value of systemic adjuvant therapy in decreasing the risk of recurrence and death in patients with early breast cancer. However, the need to identify …
Baylor Role: Collaborator
Completed
Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
PAD occurring in the legs is a serious disease that affects about 8 million people in the United States. A person's risk for PAD increases with age but can also …
Baylor Role: Lead Sponsor
Completed
Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
BACKGROUND: HIV lipodystrophy syndrome is associated with both metabolic (e.g., dyslipidemia and insulin resistance) and anthropomorphic (e.g., lipoatrophy and central obesity) abnormalities. These defects are likely to predispose HIV patients …
Baylor Role: Lead Sponsor
Completed
Biologic Correlative Taxotere/AC
Breast cancer and systemic chemotherapy: Systemic chemotherapy for operable breast cancer significantly decreases the risk of relapse and death. However, it is not possible to identify those patients at the …
Baylor Role: Collaborator